News Oxford BioMedica could get $100m following CAR-T approval UK biotech will supply key component of Novartis' newly approved cancer cell therapy
News Novartis and FDA hail 'historic' Kymriah, first ever approve... In the end, the FDA took little more than six weeks to give final approval to Kymriah, the first ever CAR-T treatment.
Events Partner Content CRISPR & Precision Gene Editing Congress - Berlin 2017 CRISPR & Precision Gene Editing Congress Berlin 2017
News Show ambition with UK life sciences plan, Novartis tells gov... Drugmaker concerned over access to new drugs
Views & Analysis Novartis move shows chief digital officers can be prime chan... GSK and Novartis have just hired execs from the world of retail to be their chief digital officers - with the hope that they can lead transformation in R&D, and relationships with customers
News Gilead strikes again, penning $5bn deal to buy Tubulis Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
